EMG
ACAD icon

ETF Managers Group’s Acadia Pharmaceuticals ACAD Stock Holding History

ETF Managers Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,384
Closed -$388K – 597
2020
Q1 		$388K Sell
9,384
-1,548
-14% -$63.8K 0.02% 245
2019
Q4 		$472K Buy
+10,932
New +$476K 0.02% 261

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ETF Managers Group's ACAD Position: Q2 2020 in Review

ETF Managers Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 9,384 shares — an estimated $388K sold.

ETF Managers Group first reported a position in ACAD in Q4 2019 and held it in 2 quarters. The position peaked at $472K in Q4 2019. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • ETF Managers Group reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • ETF Managers Group sold 9,384 Acadia Pharmaceuticals shares in Q2 2020, an estimated $388K.
  • ETF Managers Group first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • ETF Managers Group's Acadia Pharmaceuticals position peaked at $472K in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on ETF Managers Group's 13F filing for Q2 2020, filed 14 Aug 2020.